The main objective is to study the efficacy of denosumab in reducing wear-induced osteolysis
around uncemented acetabular implants used in total hip arthroplasty. Patients included in
the study will receive the same dose of 60 mg denosumab or placebo (1 ml solution) for a
total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
The primary endpoint will be the change in volume of the osteolytic lesion over 3 years
measured (measured with 3D-CT in cm³).